Lumos Labs

News

Lumos Labs has secured its first 510(k) clearance for a digital therapeutics offering, paving the way for entrance into the regulated app market.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.